Original Articles

Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets

Breast cancer vaccines composed of antigens identified by serological analysis of cDNA expression
libraries (SEREX) induce antigen specific immune responses in patients but have had disappointing clinical
benefits. While many attempts to modify the adjuvants and vaccine method have been tried, one
issue not addressed was whether the SEREX tumor-associated antigens identified from late stages of disease
were ideal targets. We questioned in the transgenic TgMMTV-neu mouse model whether the antigen

The effect of mouse strain, sex and carcinogen dose on toxicity and the development of lung dysplasia and squamous cell carcinomas in mice

In order to translate new treatments to the clinic, it is necessary to use animal models that closely recapitulate human disease.  Lung cancer develops after extended exposure to carcinogens.  It has one of the highest mutation rates of all cancer and is highly heterogenic.  Topical treatment with N-nitrosotris-(2-chloroethyl)urea (NTCU) induces lung squamous cell carcinoma (SCC) with nonsynonymous mutation rates similar to those reported for human non-small cell lung cancer.  However, NTCU induces lung cancer with variable efficacy and toxicity depending on the mouse strain.  A detailed ch

Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer

BACKGROUND:

Granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates immunity via recruitment of antigen presenting cells and tumor specific T-cell stimulation. Albumin-bound paclitaxel (nab-paclitaxel) followed by GM-CSF may enhance antitumor responses and prolong remissions in ovarian cancer. Immune phenotypes present before treatment may identify responders to chemo-immunotherapy.

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases A Phase 2 Clinical Trial

Importance  Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod.

Objective  To evaluate the safety and objective response rate (ORR) of imiquimod in combination with systemic albumin bound paclitaxel in treatment-refractory breast cancer of the chest wall.

An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis

The repertoire of antigens associated with the development of an autoimmune response in breast cancer has relevance to detection and treatment strategies. We have investigated the occurrence of autoantibodies associated with the development of triple-negative breast cancer (TNBC) in the before diagnosis setting and in samples collected at the time of diagnosis of TNBC.

Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo

BACKGROUND:

The ability of T-cells to traffic to and penetrate tumors impacts the clinical efficacy of T-cell therapy therefore methods to track transferred T-cells in vivo are needed. In this preliminary report, we evaluated the use of concurrent SPECT/PET-CT imaging to monitor the egress of HER-2/neu specific T-cells in a breast cancer patient with extensive bone-only metastatic disease.

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFa/IL17 Dependent

PURPOSE:

Infusion of HER2-specific T cells, derived from vaccine-primed patients and expanded with IL2/IL12, has induced tumor regression in a minority of patients with metastatic treatment-refractory HER2+ breast cancer. We questioned whether alteration of cytokine growth factors used to culture vaccine-primed T cells could improve antitumor activity.

Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer.

BACKGROUND:

Ovarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic. Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal opportunities for immune therapies. We sought to establish the immune profile of a murine model of ovarian cancer that allows in vivo tumor imaging and the quantitation of microscopic disease.

Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.

Recent studies in patients with breast cancer suggest the immune microenvironment influences response to therapy. We aimed to evaluate the relationship between growth rates of tumors in common spontaneous mammary tumor models and immune biomarkers evaluated in the tumor and blood. TgMMTV-neu and C3(1)-Tag transgenic mice were followed longitudinally from birth, and MPA-DMBA-treated mice from the time of carcinogen administration, for the development of mammary tumors.

Therapeutic vaccines for ovarian cancer.

While therapeutic vaccines for ovarian cancer represent only a small fraction of active clinical trials, growing interest in this area and the accumulated data supporting the use of vaccines in cancer treatment portend further expansion of trials incorporating these strategies. This review explores the rationale for the use of vaccines for the treatment of ovarian cancer. It examines vaccine platforms that have been investigated and reviews the data from these studies. We also highlight recently reported phase 2 and 3 clinical trials with clinical outcomes as endpoints.

Pages

Subscribe to RSS - Original Articles